Last updated: February 13, 2026
What Is NDC 67457-0619?
NDC 67457-0619 corresponds to Botulina toxin complex, type A, specifically a botulinum toxin product used for medical, aesthetic, or other therapeutic indications. The product is marketed under various brand names, depending on the manufacturer, including Botox, Dysport, Xeomin, and others. Precise drug specifications, formulation, approved indications, and packaging details are necessary to determine the competitive landscape.
Market Size and Segment
Estimated Market Value
- The global botulinum toxin market was valued at approximately $5.2 billion in 2022.
- Projected Compound Annual Growth Rate (CAGR): 7.4% from 2023 to 2030 (Grand View Research).
Therapeutic Indications & Usage
- Aesthetic uses: facial lines, wrinkles.
- Medical uses: cervical dystonia, spasticity, hyperhidrosis, bladder disorders.
- Expansion into new indications: migraine prevention, depression.
Key Competitors
| Product |
Brand |
Estimated 2022 Revenue |
Approval Status |
Market Share (2022) |
| Botox |
Allergan (AbbVie) |
~$3.1B |
FDA-approved |
60% |
| Dysport |
Ipsen/Convergence |
~$1.4B |
FDA-approved |
25% |
| Xeomin |
Merz |
~$0.7B |
FDA-approved |
10% |
| Others |
- |
<$0.2B |
- |
5% |
Market Dynamics
- Patent expirations for several formulations since 2020.
- New entrants and biosimilars expected to pressure prices.
- Increasing use for newer indications introduces additional revenue streams.
- Geographic expansion, particularly into Asia-Pacific and Latin America.
Pricing Structures and Trends
Current Pricing Benchmarks
| Product |
Approximate Cost per unit (USD) |
Typical Treatment Dose (units) |
Price Range (USD) |
| Botox |
$5.85 |
20-40 units per site |
$117-$234 per treatment site |
| Dysport |
$4.50 |
50-100 units per treatment |
$225-$450 |
| Xeomin |
$4.75 |
20-50 units |
$95-$237 |
Pricing Factors
- Geographic location influences prices; U.S. higher than international markets.
- Reimbursement policies impact pricing strategies.
- Packaging (single-use vials vs. multi-dose) affects cost.
Recent Trends
- Slight price declines observed since 2020, driven by competition.
- Manufacturers bundle products for clinics.
- Volume discounts and loyalty programs are prevalent.
Price Projections (2023-2030)
Assumptions Include:
- Market growth at CAGR 7.4%.
- Continued patent expiries for leading brands, boosting generic/biosimilar entry.
- New indications and formulations gain regulatory approval.
- Reimbursement and healthcare policies evolve toward cost containment.
| Year |
Estimated Price per Unit (USD) |
Remarks |
| 2023 |
$4.75-$5.10 |
Baseline, reflecting slight decrease |
| 2025 |
$4.50-$4.85 |
Increased biosimilar competition |
| 2027 |
$4.20-$4.60 |
Further market saturation; price stabilization |
| 2030 |
$4.00-$4.30 |
Likely average, with regional variation |
Market Impact of Biosimilars
- Introduction of biosimilars expected to reduce prices by up to 20-30%.
- Key markets for biosimilar entry include Europe and Asia-Pacific, with regulatory pathways established.
Forecast Summary
Total market revenue in 2023 for NDC 67457-0619–related products could range from $850 million to $1 billion, considering market share, with prices averaging approximately $4.75 per unit. By 2030, prices may decline marginally, with total revenue projected to grow at a CAGR of 7.4%, reaching around $9 billion globally, presuming increasing utilization and expanded indications.
Regulatory and Policy Impacts
- FDA approvals for new indications will expand market potential.
- Reimbursement changes can influence pricing; Medicaid/Medicare policies in the U.S. favor cheaper alternatives.
- Intellectual property challenges may accelerate biosimilar entry, further lowering prices.
Key Takeaways
- The market for botulinum toxin products is expanding, driven by aesthetics and medical indications.
- Price per unit has been gradually declining due to fierce competition and biosimilar entry.
- Projected prices suggest a slight further decrease over the next decade.
- Market revenue growth is tightly linked to new indications, geographic expansion, and regulatory landscape.
- Trends indicate ongoing downward pressure on prices, but overall market value continues to grow thanks to increased usage.
FAQs
-
What factors could cause prices to fall faster than projected?
Increased biosimilar competition, regulatory delays for new indications, or reimbursement policies favoring lower-cost options could accelerate price reductions.
-
How does regional variation affect pricing?
Prices are higher in the U.S. due to administrative reimbursement frameworks, while emerging markets in Asia and Latin America generally have lower prices due to competitive dynamics and different healthcare policies.
-
What is the impact of new indications on market size?
Expansion into conditions like depression and chronic pain could significantly increase treatment volume, supporting higher revenue despite price declines.
-
Are biosimilars a dominant threat?
Yes, biosimilars are expected to account for a growing share, reducing brand-name product prices and sharply increasing market competition.
-
What is the regulatory outlook for biosimilar approval?
Regulators in the U.S. and Europe have established pathways, leading to accelerated approval timelines and increased biosimilar entries by mid-decade.
References
[1] Grand View Research, “Botulinum Toxin Market Size, Share & Trends Analysis Report,” 2022.
